SCHEMBL1689385

SCHEMBL1689385

[CH2]CCCNC(=O)C(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.50
CYP2C19 P33261 2/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
ALDH1A2 O94788 1/20 0.41
ALDH1A1 P00352 1/20 0.41
ALDH2 P05091 1/20 0.41
ALDH1A3 P47895 1/20 0.41
USP2 O75604 1/20 0.38
TSHR P16473 1/20 0.38
DPP7 Q9UHL4 2/20 0.37
MTNR1A P48039 4/20 0.37
MTNR1B P49286 4/20 0.37
DRD2 P14416 1/20 0.37
DRD4 P21917 1/20 0.37
MEN1 O00255 2/20 0.36
PTGS1 P23219 1/20 0.36
KCNH2 Q12809 1/20 0.36
MMP8 P22894 1/20 0.36
MAPK1 P28482 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9113674 0.91 ALDH1A1 (0.48) KMT2ACYP2C19CYP2D6CYP2C9ALDH1A2
SCHEMBL843281 0.86
SCHEMBL861034 0.85 KMT2A (0.57) KMT2ACYP2C19CYP2D6CYP2C9ALDH1A2
SCHEMBL22917014 0.85 KMT2A (0.57) KMT2ACYP2C19CYP2D6CYP2C9ALDH1A2
SCHEMBL23839910 0.83 ALDH1A1 (0.58) KMT2ACYP2C19CYP2D6CYP2C9ALDH1A2
SCHEMBL17777241 0.83 ALDH1A1 (0.58) KMT2ACYP2C19CYP2D6CYP2C9ALDH1A2
SCHEMBL23188735 0.83 ALDH1A1 (0.58) KMT2ACYP2C19CYP2D6CYP2C9ALDH1A2
SCHEMBL12131751 0.80 USP2 (0.55) KMT2ACYP2C19CYP2D6CYP2C9ALDH1A2
SCHEMBL10664111 0.79 ALDH1A1 (0.41) KMT2ACYP2C19CYP2D6CYP2C9ALDH1A2
SCHEMBL1499653 0.79 PTGS1 (0.55) KMT2ACYP2C19CYP2D6CYP2C9ALDH1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8343993-B2 Hydroxyalkyl substituted imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-01-01 US claimed
US-8178677-B2 Hydroxyalkyl substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-05-15 US claimed
US-20090253695-A1 Hydroxyalkyl Substituted Imidazonaphthyridines COLEY PHARMACEUTICAL GROUP, INC, (US) 2009-10-08 US claimed
US-20090029988-A1 Hydroxyalkyl Substituted Imidazoquinolines COLEY PHARMACEUTICAL GROP, INC. (US) 2009-01-29 US claimed
EP-1851218-A2 HYDROXYALKYL SUBSTITUTED IMIDAZOQUINOLINE COMPOUNDS AND METHODS 3M Innovative Properties Company (US) 2007-11-07 EP claimed
WO-2006091567-A2 HYDROXYALKYL SUBSTITUTED IMIDAZOQUINOLINE COMPOUNDS AND METHODS COLEY PHARMACEUTICAL GROUP, INC. (US) 2006-08-31 WO claimed
US-11591426-B2 Copolymer, wetting agent, medical device, and method for producing same TORAY INDUSTRIES, INC. (JP) 2023-02-28 US disclosed
EP-3438144-B1 COPOLYMER, WETTING AGENT, MEDICAL DEVICE, AND METHOD FOR PRODUCING SAME TORAY INDUSTRIES (JP) 2021-06-30 EP disclosed
US-20210015960-A1 COPOLYMER, WETTING AGENT, MEDICAL DEVICE, AND METHOD FOR PRODUCING SAME TORAY INDUSTRIES, INC. (JP) 2021-01-21 US disclosed
US-20190099511-A1 COPOLYMER, WETTING AGENT, MEDICAL DEVICE, AND METHOD FOR PRODUCING SAME TORAY INDUSTRIES, INC. (JP) 2019-04-04 US disclosed
EP-3438144-A1 COPOLYMER, WETTING AGENT, MEDICAL DEVICE, AND METHOD FOR PRODUCING SAME Toray Industries, Inc. (JP) 2019-02-06 EP disclosed
US-8846710-B2 Method of preferentially inducing the biosynthesis of interferon 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-09-30 US disclosed
US-8343993-B2 Hydroxyalkyl substituted imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-01-01 US disclosed
EP-1851218-A2 HYDROXYALKYL SUBSTITUTED IMIDAZOQUINOLINE COMPOUNDS AND METHODS 3M Innovative Properties Company (US) 2007-11-07 EP disclosed
WO-2006091647-A2 METHOD OF PREFERENTIALLY INDUCING THE BIOSYNTHESIS OF INTERFERON COLEY PHARMACEUTICAL GROUP, INC. (US) 2006-08-31 WO disclosed
WO-2006091567-A2 HYDROXYALKYL SUBSTITUTED IMIDAZOQUINOLINE COMPOUNDS AND METHODS COLEY PHARMACEUTICAL GROUP, INC. (US) 2006-08-31 WO disclosed
EP-0721454-A1 NEW PYRAZOLE DERIVATIVES AS ANGIOTENSIN II ANTAGONIST J. URIACH & CIA. S.A. (ES) 1996-07-17 EP disclosed
US-5017724-A Antihypoxic, CNS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1991-05-21 US disclosed
EP-0267024-B1 HYDROFLUORENE DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1991-05-02 EP disclosed
EP-0267024-A2 Hydrofluorene derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1988-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253695-A1 Hydroxyalkyl Substituted Imidazonaphthyridines IFNG, IFNAR1, IRF3 KMT2A 2533/4885CYP2C19 3019/4885CYP2D6 1165/4885
US-20090029988-A1 Hydroxyalkyl Substituted Imidazoquinolines IFNG, IRF3, IFNAR1 KMT2A 1364/4885CYP2C19 2644/4885CYP2D6 770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.